

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED WITH JAB-21822 IN THE PHASE IIa TRIAL ON KRAS G12C AND STK11 CO-MUTATION

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that, on August 31, 2022, the Group has dosed the first non-small cell lung cancer (NSCLC) patient with KRAS G12C and STK11 co-mutation in the Phase IIa trial of KRAS G12C inhibitor JAB-21822 in China.

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio utilizing the allosteric inhibitor technology, which is now used as the front-line treatment for advanced or metastatic NSCLC patients with KRAS G12C and STK11 co-mutation.

In China, there are approximately 40,000 new patients with tumors harboring KRAS G12C mutation every year. STK11 is an in-parallel biomarker of KRAS G12C. According to relevant studies, NSCLC patients with STK11 and KRAS G12C co-mutation receiving KRAS G12C inhibitor treatment have a higher objective response rate in clinical trial.

JAB-21822, a KRAS G12C inhibitor of Jacobio, is the best-in-class potential project for KRAS G12C inhibitors. The preliminary clinical data of the Phase I trial of JAB-21822 published at the 2022 annual meeting of American Society of Clinical Oncology (ASCO) shows that as of April 1, 2022, a total of 72 patients with advanced solid tumors were enrolled, and efficacy was assessed for 32 NSCLC patients with KRAS G12C mutation. The overall response rate (ORR) was 56.3% (18/32) and the disease control rate (DCR) was 90.6% (29/32).

Currently, JAB-21822 is simultaneously undergoing clinical trials for monotherapy and combination therapy in China, the United States and Europe, including the monotherapy for NSCLC with KRAS G12C mutation, pancreatic ductal carcinoma and colorectal cancer; the combination therapy with EGFR monoclonal antibody; and the combination therapy with JAB-3312, a self-developed SHP2 inhibitor of the Company.

About JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated NSCLC in the front-line setting; combination therapy with SHP2 inhibitor, anti-PD-1 monoclonal antibody and cetuximab.

Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the JAB-21822 and related combination therapy will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, September 1, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Daqing CAI as independent non-executive Directors.